WEKO3
インデックスリンク
アイテム
Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer
https://fmu.repo.nii.ac.jp/records/2001971
https://fmu.repo.nii.ac.jp/records/2001971a2beea6a-b8e7-4990-b3ae-4a852d6e07bf
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
FksmJMedSci_65_p6.pdf (346.4 KB)
|
|
| Item type | デフォルトアイテムタイプ（フル）fmu(1) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2019-04-22 | |||||||||||||||||||||||||
| タイトル | ||||||||||||||||||||||||||
| タイトル | Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer | |||||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||||||
| 作成者 |
Hayase, Suguru
× Hayase, Suguru
× Yamada, Leo
× Ujiie, Daisuke
× Nirei, Azuma
× Tada, Takeshi
× Hanayama, Hiroyuki
× Monma, Tomoyuki
× Saze, Zenichiro
× Ohki, Shinji
× Kono, Koji
|
|||||||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||||||
| 権利情報Resource | https://creativecommons.org/licenses/by-nc-sa/4.0/ | |||||||||||||||||||||||||
| 権利情報 | © 2019 The Fukushima Society of Medical Science. This article is licensed under a Creative Commons [Attribution-NonCommercial-ShareAlike 4.0 International] license. | |||||||||||||||||||||||||
| 内容記述 | ||||||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||||||
| 内容記述 | Introduction Recently in Japan, Ramucirumab (RAM) became the first anti-angiogenic agent to be approved for second-line treatment of gastric cancer. In the present study, we aimed to evaluate the efficacy and safety of RAM plus paclitaxel (PTX) in patients with unresectable and recurrent gastric cancer in our institution. Patients and Methods The subjects were 11 patients with unresectable and recurrent gastric cancer who received RAM plus PTX as a second- or later-line treatment at our hospital between June 2015 and September 2017, after the failure of previously-attempted treatments. We assessed the efficacy and safety of RAM plus PTX, and also compared them between patients aged <75 years (n=6) and those aged ≥75 (n=5), by performing a retrospective analysis based on the data obtained from daily clinical practice for gastric cancer treatment. Results Objective tumor response was observed in one of the 11 patients (9.1%) with partial response, and disease control was seen in the remaining 10 (90.9%). The median overall survival (OS) and progression-free survival (PFS) of the patients were 20.8 months (95% CI 7.8-NA (not applicable)) and 11.3 months (95% CI 6.5-NA), respectively. There were no serious adverse events. The median OS for the <75 years group and ≥75 years group was NA (due to short follow-up period) and 20.8 months (p = 0.336), respectively, and their respective median PFS rates were 9.4 and 11.3 months (p = 0.492). The difference of rate of adverse events was not significant between the two age groups in the present study, though the number of adverse events was not sufficient. Conclusion The results of the present study suggest that the combination chemotherapy of RAM and PTX was effective in unresectable and recurrent gastric cancer patients as a second- or later-line therapy, and has been shown to be safe and feasible in elderly patients. | |||||||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||||||
| 出版者 | The Fukushima Society of Medical Science | |||||||||||||||||||||||||
| 言語 | ||||||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||||||
| 書誌情報 |
en : Fukushima Journal of Medical Science 巻 65, 号 1, p. 6-12, 発行日 2019 |
|||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||||||
| 関連識別子 | https://doi.org/10.5387/fms.2018-12 | |||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 識別子タイプ | PMID | |||||||||||||||||||||||||
| 関連識別子 | 30996218 | |||||||||||||||||||||||||
| 関連情報 | ||||||||||||||||||||||||||
| 識別子タイプ | ICHUSHI | |||||||||||||||||||||||||
| 関連識別子 | 2020047836 | |||||||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||||||||
| 収録物識別子 | 0016-2590 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||||||
| 収録物識別子 | 2185-4610 | |||||||||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||||||||||
| 収録物識別子 | AA0065246X | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | advanced gastric cancer | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | chemotherapy | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | elderly | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | paclitaxel | |||||||||||||||||||||||||
| 主題 | ||||||||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||||||
| 主題 | ramucirumab | |||||||||||||||||||||||||
